Axsome Therapeutics (AXSM) Return on Equity (2016 - 2026)

Axsome Therapeutics has disclosed Return on Equity across 11 years of filings, most recently posting 0.03% for Q1 2026.

• Return on Equity for Q1 2026 came in at 0.03%, up 2.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.03% (up 2.0% YoY), and the FY2025 annual result was 0.03%, changed 0.0% from the prior year.
• Return on Equity came in at 0.03% for Q1 2026 at Axsome Therapeutics, down from 0.02% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.01% in Q3 2023 to a low of 0.1% in Q2 2022.
• The 5-year median for Return on Equity is 0.02% (2024), against an average of 0.03%.
• Across the five-year window, Return on Equity decreased 9 bps in 2022 and gained 9 bps in 2023, its largest moves.
• Axsome Therapeutics' Return on Equity stood at 0.01% in 2022, then climbed by 26 bps to 0.01% in 2023, then plunged by 269 bps to 0.04% in 2024, then jumped by 41 bps to 0.02% in 2025, then dropped by 17 bps to 0.03% in 2026.
• The last three Return on Equity figures came in at 0.03% (Q1 2026), 0.02% (Q4 2025), and 0.03% (Q3 2025), per Business Quant data.